Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cybin Inc. Common Shares
(NY:
CYBN
)
9.290
UNCHANGED
Streaming Delayed Price
Updated: 8:00 PM EST, Feb 18, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
7
Open
9.290
Bid (Size)
9.100 (23)
Ask (Size)
10.23 (1)
Prev. Close
9.290
Today's Range
9.290 - 9.290
52wk Range
6.500 - 19.85
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
MGM Resorts To Rally Around 75%? Here Are 10 Top Analyst Forecasts For Thursday
February 13, 2025
Via
Benzinga
RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care.
February 12, 2025
The Senate will vote Thursday on whether to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks.
Via
Investor's Business Daily
Performance
YTD
-1.28%
-1.28%
1 Month
-3.43%
-3.43%
3 Month
-15.55%
-15.55%
6 Month
-7.40%
-7.40%
1 Year
-33.93%
-33.93%
More News
Read More
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports Q3 Financials, Advances Clinical Programs
February 11, 2025
Via
Investor Brand Network
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
February 10, 2025
From
Cybin Inc.
Via
Business Wire
RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box.
February 04, 2025
Via
Investor's Business Daily
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Launches Strategic Partnership Program with Segal Trials for Phase 3 MDD Study
January 15, 2025
Via
Investor Brand Network
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
January 15, 2025
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights 2024 Achievements and Outlines Key 2025 Milestones
January 13, 2025
Via
Investor Brand Network
Exposures
Product Safety
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
January 13, 2025
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate in Lytham Partners Healthcare Summit
January 10, 2025
Via
Investor Brand Network
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
January 09, 2025
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights Promising Advances in Depression and Anxiety Treatment at ACNP Annual Meeting
December 10, 2024
Via
Investor Brand Network
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
December 10, 2024
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Water Tower Research Fireside Chat
December 04, 2024
Via
Investor Brand Network
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
December 04, 2024
From
Cybin Inc.
Via
Business Wire
Is Your Mind Ready to Consider Investing in Psychedelics Stocks?
November 29, 2024
Via
The Motley Fool
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports Sustained 12-Month Efficacy for CYB003 in Treating Major Depressive Disorder
November 18, 2024
Via
Investor Brand Network
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
November 18, 2024
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present Key 12-Month Data and Phase 3 Program Insights for CYB003 in Upcoming Webcast
November 14, 2024
Via
Investor Brand Network
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
November 14, 2024
From
Cybin Inc.
Via
Business Wire
Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression
November 13, 2024
Via
Benzinga
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
November 13, 2024
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Begins Phase 3 Trials of CYB003 for Depression, Building on Promising Phase 2 Results
November 13, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Present Advancements in Mental Health Treatment at Milken Institute Summit
October 31, 2024
Via
Investor Brand Network
Cybin to Participate at the 2024 Milken Institute Future of Health Summit
October 31, 2024
From
Cybin Inc.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.